Administration of H1 and H2 antagonists for chemoprophylaxis: a double-blind, placebo-controlled study in healthy volunteers.
A double-blind, placebo-controlled trial was performed to establish the duration of action of antihistamines and their ability to attenuate the adverse affects associated with histamine release. Thirty volunteers were assigned randomly to receive either placebo or a combination of the H1 blocker dimetindene maleate (0.1 mg/kg) and the H2 blocker cimetidine (5 mg/kg). A bolus dose of histamine (450 ng/kg) was given 15 minutes after antihistamine or placebo treatment and repeated after 2, 4, and 6 hours. Cardiovascular variables, plasma histamine levels, cutaneous manifestations, and objective and subjective signs and symptoms associated with histamine release were determined before and after each histamine injection. Although many of the signs of histamine release, including erythema and metallic taste, could be attenuated effectively for 6 hours with antihistamine treatment, the protection against histamine-induced flush and headache diminished after 2 hours. Statistically significant protection against histamine-mediated tachycardia persisted for only 2 hours. Antihistamine treatment significantly reduced the increase in plasma histamine levels after the first histamine injection but did not alter the levels after subsequent histamine injections. The currently recommended administration regimen for prophylaxis with antihistamines is insufficient to prevent histamine-mediated side effects, and additional doses may be required after 4 hours to achieve appropriate chemoprophylaxis.
Doenicke
A
A
Institute for Anesthesiology, Ludwig-Maximilians-University of Munich, Germany.
Moss
J
J
Toledano
A
A
Hoernecke
R
R
Lorenz
W
W
Ostwald
P
P
D000328:Adult; D001794:Blood Pressure / Q000187:drug effects*; D002927:Cimetidine / Q000494:pharmacology*; D004115:Dimethindene / Q000494:pharmacology*; D004311:Double-Blind Method; D004890:Erythema / Q000517:prevention & control; D005260:Female; D006261:Headache / Q000517:prevention & control; D006339:Heart Rate / Q000187:drug effects*; D006632:Histamine / Q000008:administration & dosage* / Q000009:adverse effects; D006634:Histamine H1 Antagonists / Q000494:pharmacology*; D006635:Histamine H2 Antagonists / Q000494:pharmacology*; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D013610:Tachycardia / Q000517:prevention & control
D006634:Histamine H1 Antagonists; D006635:Histamine H2 Antagonists; D004115:Dimethindene; D002927:Cimetidine; D006632:Histamine